If left untreated, these manifestations will trigger RPE detachment, subretinal fibrosis, and RPE cell death followed by photoreceptor death, deterioration of vision, and ultimately blindness.[70] Vascular endothelial growth factors (VEGF) have been unequivocally established as the primary therapeutic target for CNV. The gene discussed is VEGFA; the disease is blindness (disorder).